Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.